Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KIDS
KIDS logo

KIDS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy OrthoPediatrics Corp (KIDS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
19.820
1 Day change
-3.08%
52 Week Range
23.700
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

KIDS is not a strong buy right now for a beginner-focused, long-term investor with $50,000-$100,000 to deploy. The stock has constructive technical momentum and some supportive hedge fund buying, but there is no AI Stock Picker or SwingMax buy signal today, analyst views are mixed with a recent target cut to $17 and a Hold rating, and the options market shows extremely high implied volatility without meaningful trading activity. My direct view: wait for a better entry rather than buying immediately.

Technical Analysis

The chart structure is bullish in the near term: SMA_5 is above SMA_20 and SMA_20 is above SMA_200, which supports an uptrend. MACD histogram is positive and expanding, confirming upward momentum. RSI_6 at 63.758 is elevated but not overbought, so the stock still has room to run. Price at 19.98 is above the pivot of 19.371 and below resistance at 20.395, meaning it is testing the upper part of its short-term range. Overall, the technical trend is positive, but not backed by a strong proprietary buy trigger.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is not very informative because today’s option volume is 0 and put/call open interest is effectively neutral at 0. However, the implied volatility is extremely high at 329.88 with IV percentile at 100, which signals very expensive options pricing and heightened uncertainty. The options tape does not show a clear bullish crowding signal.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
1
Buy
9

Positive Catalysts

  • Hedge funds are buying, with buying up 114.29% over the last quarter, which is a positive institutional signal. Technical momentum is healthy with bullish moving averages and a positive MACD expansion. Recent analyst commentary from Canaccord was constructive, raising the target to $25 and maintaining a Buy rating based on expected profitable growth and FCF breakeven in FY26.

Neutral/Negative Catalysts

  • Truist recently cut its price target to $17 from $20 and kept a Hold rating, citing group multiple compression. There was no news in the last week to act as a fresh catalyst. Options data shows very high implied volatility without supporting volume, which makes the setup less attractive for immediate entry. The stock trend model suggests a 60% chance of -8.47% over the next week, which argues against chasing the current price.

Financial Performance

No usable latest-quarter financial snapshot was available due to an error, so there is no confirmed quarter-over-quarter revenue or earnings breakdown to assess directly. Based on the analyst commentary, the company appears to be progressing toward profitable growth, with expectations for FCF breakeven in FY26, but the provided data does not include the latest quarter season or hard financial figures.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed. On 2026-04-24, Canaccord raised its price target to $25 from $24 and kept a Buy rating, highlighting the beginning of an NPL supercycle and expected profitable growth. On 2026-05-01, Truist lowered its target to $17 from $20 and kept a Hold rating, citing recent multiple compression despite balanced sales upside and strong outside-U.S. performance. Net takeaway: the Wall Street view is split, with upside potential acknowledged but not strongly endorsed at current levels.

Wall Street analysts forecast KIDS stock price to rise
5 Analyst Rating
Wall Street analysts forecast KIDS stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.450
sliders
Low
20
Averages
23
High
26
Current: 20.450
sliders
Low
20
Averages
23
High
26
Truist
Hold
downgrade
$20 -> $17
AI Analysis
2026-05-01
Reason
Truist
Price Target
$20 -> $17
AI Analysis
2026-05-01
downgrade
Hold
Reason
Truist lowered the firm's price target on OrthoPediatrics to $17 from $20 and keeps a Hold rating on the shares. The firm notes that sales upside relative to consensus was balanced across product segments and outside-U.S. business was strong geographically, but its price target on the stock is cut to reflect the recent group multiple compression, the analyst tells investors in a research note.
Canaccord
Buy
maintain
$24 -> $25
2026-04-24
Reason
Canaccord
Price Target
$24 -> $25
2026-04-24
maintain
Buy
Reason
Canaccord raised the firm's price target on OrthoPediatrics to $25 from $24 and keeps a Buy rating on the shares. The firm updated its model ahead of Q1 results. They continue to like the shares which is at the beginning of an NPL supercycle. The company executed on a beat in the Q4 while maintaining its conservative approach to guidance leaving out more variable elements which, if they improve, provide upside, while setting a baseline from which the company can profitably grow, evidenced by expectations for FCF breakeven in FY26.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for KIDS
Unlock Now

People Also Watch